Hello! I'm your financial analysis assistant. This article about Alibaba Health tells a very typical and compelling story: a once highly anticipated "tech-medical" giant has realized, after ten years, that it is essentially still a retail company that sells medicines. The capital market is voting with its feet, reevaluating its value accordingly.
To help you understand the intricacies behind this, I'll first summarize the key points in one sentence and then break down the analysis into five aspects for you in plain language.
📌 Key Points Summary
Alibaba Health delivered what appeared to be a solid set of financial results for the 2026 fiscal year (revenue of 34.2 billion yuan, profit of 1.9 billion yuan, both showing growth), but the capital market wasn't impressed. It was removed from the "tech index," and a new CEO was appointed. The fundamental reason is that, despite its tech and medical facade, 86% of its revenue still comes from traditional online medicine sales (B2C retail). This business model is experiencing slow growth, and it faces fierce competition from companies like JD.com and Meituan. The company is trying to pivot with AI-based medical solutions (such as hydrogen ion technology), but AI has yet to generate significant profits or establish a competitive edge. In short, the growth of its core business (medicine sales) is weak, and its new initiatives (AI/medical) haven't taken off, causing its valuation to shift from "high-tech" to "traditional retail."
---
🔍 In-Depth Analysis: Five Aspects Explained in Simple Terms
1. Performance Truth: Profit Growth, but It's Due to Cost Cuts, Not Sales
Looking at the numbers, Alibaba Health earned a net profit of 1.936 billion yuan in 2026, a 35% increase from the previous year. On the surface, this seems impressive, but upon closer inspection, there are issues:
- Revenue Structure Unchanged: For every 100 yuan earned, 98 yuan comes from medicine sales (direct sales and through its e-commerce platform), with only a little over 2 yuan from medical services and digital services. This indicates that its core business remains that of a pharmaceutical retailer, not a technology company.
- How Did the Profit Come About? The gross margin decreased by 0.3 percentage points, yet net profit increased significantly. This is because the company reduced costs related to delivery, warehousing, and labor. In other words, it sold more goods while spending less on each delivery.
- Implication: This type of profit growth based on cost-cutting has its limits. If competition intensifies and delivery costs can't be further reduced, or if price wars break out, profits will decline. Unlike technology companies that earn high margins through barriers, Alibaba Health relies on scale like a supermarket.
2. Market Status: Removed from the "Tech Circle" Due to Lack of Technological Depth
On September 11, Alibaba Health was removed from the Hong Kong Stock Exchange's Tech 100 index. This is more than just a change in listing; it represents a reevaluation of the company's identity by the capital market.
- Why the Removal? Current tech indices favor companies in AI and hard technology (such as chips and semiconductors). Although Alibaba Health includes "health" in its name and offers digital services, its core business is still about generating revenue from traffic and drug transactions. Investors see it as an internet-based pharmaceutical wholesaler/retailer, not a technology company with core technologies.
- Comparison with JD Health: JD Health earned 73.4 billion yuan in 2025, more than twice that of Alibaba Health, with twice the growth rate. JD Health leverages its strong supply chain and logistics to excel in medicine sales. Alibaba Health has fallen behind in terms of scale in the main battlefield of "remote e-commerce" (ordering and delivery by courier).
- Industry Trends: The overall growth rate of the pharmaceutical e-commerce industry has slowed from 21% to 9.4%. The market is becoming more competitive, with more players (JD, Meituan, Douyin), and traditional pharmacies are closing, indicating a shift to a phase of niche competition rather than rapid expansion.
3. Competitive Dilemma: Remote E-commerce Can't Meet Immediate Needs
The article highlights the challenge: "Remote e-commerce can't solve the immediate needs of patients." For example, ordering from Taobao/Tmall and having medicines delivered by courier usually takes 1-3 days, while Meituan/DJ Home offers same-day or hour-long delivery.
- JD Health's Advantage: It has already implemented instant delivery services, combining online platforms with local delivery.
- Meituan's Strength: Meituan benefits from its local user base, giving it a natural advantage in instant delivery.
- Alibaba Health's Challenge: Although Alibaba Health also offers flash sales, its instant delivery capability is not as prominent. Patients in urgent need of medicine are more likely to choose Meituan or JD Health over Alibaba Health, undermining its core advantage of having a large user base.
4. The AI Initiative: Is Hydrogen Ion Technology Just a Fancy Concept or a Real Business?
To move away from the label of a "medicine seller," Alibaba Health invested in AI-based medical solutions, launching "Hydrogen Ion" (a doctor version of GPT).
- Strengths: It has obtained licenses from three top medical journals (BMJ, NEJM, JAMA), which provides a competitive advantage in terms of content rights.
- Challenges:
1. Lack of Transparency: It's unclear how many doctors are using the technology and how frequently. By comparison, OpenEvidence has 750,000 registered doctors and receives 20 million consultations per month. Alibaba Health's AI is still in the promotional phase, lacking evidence of widespread use.
2. Internal Competition: There are similar products within the Alibaba Group, and Ant Group controls the traffic channels for these services, making it difficult to build a cohesive strategy.
3. Payment Issues: The biggest question for AI in healthcare is who will pay for its use: doctors, hospitals, or pharmaceutical companies? No clear answer yet. If AI can't be integrated into payment systems (such as healthcare insurance), it remains just a useful tool, not a profitable product.
5. The Change in Leadership: From "Broad Coverage" to "Focusing on Technology"
Shen Difan resigned as CEO, and Yu Yong took over. Shen continued to oversee the AI business (Hydrogen Ion). This leadership change reflects a strategic shift:
- Shen Difan's Dilemma: As CEO, he had to manage both the retail business and AI initiatives. AI doesn't contribute to profits in the short term and requires significant investment, while the retail business is growing slowly, putting pressure on the company.
- Yu Yong's Task: With experience in B2B services, Yu Yong needs to address issues related to supply chain efficiency and service quality for hospitals, pharmacies, and pharmaceutical companies. He must show that Alibaba Health can create value beyond just selling medicines.
- Shen's Role: By stepping back to focus on AI, the company acknowledges that AI alone isn't enough to support its overall value. It may need to be developed separately or even seek additional funding or a separate listing to prove its potential.
💡 Lessons for Everyone
1. Don't Be Misled by Names: Don't assume companies like Alibaba Health or JD Health are high-tech just because of their names. Look at their revenue sources. If most of their income comes from sales, they are still retailers subject to the same market cycles.
2. Focus on Instant Delivery: In healthcare, speed is becoming a key factor. In the future, the company that delivers medicines quickly will have a competitive advantage.
3. AI in Healthcare is Still in Its Early Stages: Despite the popularity of AI, commercialization in healthcare is challenging due to safety concerns and complex payment structures. Most AI initiatives are still in the conceptual phase.
4. Changing Investment Logic: The capital market is more rational, focusing on cash flow and competitive advantages. Alibaba Health's removal from the tech index reminds investors to evaluate a company based on its actual revenue sources, not its claims.
In summary: Alibaba Health is in a challenging period where its core business is struggling, and its new AI initiatives haven't taken off. New CEO Yu Yong needs to demonstrate that the company can provide real value to hospitals, pharmacies, and pharmaceutical companies beyond just selling medicines.